Assess whether biosimilarity is analytically justified (e29dca)

Situation

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — pediatric investigation plan vs. disease epidemiology — after a DSMB note on an imbalance that is not yet a signal. If pediatric investigation plan vs. disease epidemiology cannot support biosimilarity is analytically justified, the honest Pharma & Life Sciences output is hold.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using pediatric investigation plan vs. disease epidemiology after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• RWE evidence-strategy director can defend Proceed under protocol from pediatric investigation plan vs. disease epidemiology after a DSMB note on an imbalance that is not yet a signal in a Pharma & Life Sciences challenge.
• RWE evidence-strategy director cannot defend Proceed under protocol from pediatric investigation plan vs. disease epidemiology; Pause the pathway is what the extract actually supports after a DSMB note on an imbalance that is not yet a signal.
• A DSMB note on an imbalance that is not yet a signal never reached the population in pediatric investigation plan vs. disease epidemiology — reopen intake, do not close biosimilarity is analytically justified.
• Two facts in pediatric investigation plan vs. disease epidemiology after a DSMB note on an imbalance that is not yet a signal conflict for RWE evidence-strategy director; hold this Pharmacovigilance file.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in pediatric investigation plan vs. disease epidemiology after a DSMB note on an imbalance that is not yet a signal.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• For this Pharma & Life Sciences Pharmacovigilance file, read pediatric investigation plan vs. disease epidemiology against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move biosimilarity is analytically justified for RWE evidence-strategy director.

Recommendation